OT mobile menu

Search form


Skin Cancer / Melanoma Targets

FDA Approves Opdivo-Yervoy Combo for Unresectable or Metastatic Melanoma

The FDA has approved Opdivo in combination with Yervoy for treating unresectable or metastatic melanoma.

Skin Cancer / Melanoma Targets

Penn State College of Medicine researchers have discovered a new class of drugs that may keep a deadly form of skin cancer from becoming resistant to treatment.

Investigators at University of California, Irvine report that they have uncovered a specific mutation in the ATR gene that allows melanoma tumor cells to remain undetected by the immune system.

Dietary fat intake might promote the growth of melanoma tumors harboring BRAF V600E mutations, and lipid-lowering drugs can slow that growth, according to a mouse study.

There is a lot of interest in a new treatment that kills approximately 90% of melanoma cancer cells, an astounding accomplishment for Richard Neubig, MD, PhD, who serves as chairperson of pharmacology toxicology at Michigan State University.

Canadian researchers might have discovered why melanoma is more aggressive in men than women: decreased expression of a melanoma tumor suppressor gene on the sex chromosomes.

Scientists have found a way to detect earlier if Merkel cell carcinoma (MCC) is recurring in patients. They have published a paper in the journal Cancer demonstrating how an immune system marker may be able to outperform and supplement imaging studies for recurrence of MCC.

Researchers from Moffitt Cancer Center’s Integrated Mathematical Oncology (IMO) Department are overcoming some of the limitations of common preclinical experiments and clinical trials by studying cancer through mathematical modeling.


Subscribe to Skin Cancer / Melanoma Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.